Clear clinical benefit with cobimetinib added to vemurafenib in advanced BRAFV600-mutant melanoma

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Cobimetinib combined with vemurafenib as a first-line approach improved survival outcomes in patients with advanced BRAFV600-mutant melanoma.
Study design
  • Phase 3 randomized multicenter study that evaluated the efficacy and safety of a combination of cobimetinib and vemurafenib vs placebo...